Related Experiment Videos
A Cautionary Note on Regional Consistency Evaluation With Multiple Primary Endpoints in Multiregional Clinical Trials
1Astellas Pharma Inc., Tokyo, Japan.
Pharmaceutical Statistics
|August 14, 2026
Summary
Evaluating regional consistency in multiregional clinical trials (MRCTs) requires careful adjustment when multiple endpoints are used. This study proposes adjusted thresholds to prevent inflated null regional consistency probabilities (RCPs) under common multiplicity procedures.
Area of Science:
- Clinical Trials
- Biostatistics
- Regulatory Science
Background:
- Multiregional clinical trials (MRCTs) require evaluation of regional consistency probabilities (RCPs) alongside overall trial power.
- Existing guidance, like the Japanese Ministry of Health, Labour and Welfare's Method 1 and Method 2, addresses regional consistency criteria.
- The impact of multiplicity adjustments on RCP evaluation in MRCTs with multiple primary endpoints remains underexplored.
Purpose of the Study:
- To investigate the inflation of null RCPs when standard multiplicity adjustments (e.g., Bonferroni) are applied to regional consistency evaluation in MRCTs.
- To propose and validate adjusted consistency thresholds that maintain the null RCP at its single-endpoint level.
- To assess the performance of these adjusted thresholds under various multiplicity adjustment procedures.
Main Methods:
- Demonstrated the monotone inflation of null RCPs with increasing endpoints under unadjusted Bonferroni correction for both Method 1 and Method 2.
- Developed and proposed adjusted consistency thresholds using a root-finding algorithm to restore null RCPs.
- Conducted numerical studies to evaluate the proposed thresholds' impact on RCP under alternative hypotheses and their compatibility with step-down procedures (Holm, Hochberg, Hommel).
Main Results:
- Unadjusted consistency thresholds combined with Bonferroni correction lead to inflated null RCPs, especially with more endpoints.
- The proposed adjusted consistency thresholds effectively restore the null RCP to the single-endpoint level.
- Adjusted thresholds cause only a minor decrease in RCP under the alternative hypothesis.
- Bonferroni-derived thresholds also control null RCP inflation when used with Holm, Hochberg, and Hommel procedures.
Conclusions:
- Standard multiplicity adjustments can inflate null RCPs in MRCTs with multiple endpoints, potentially leading to erroneous conclusions about regional consistency.
- The proposed adjusted consistency thresholds provide a statistically sound method to control for multiplicity in RCP evaluation.
- The developed methodology and available R package ('rcpmcp') offer practical tools for designing MRCTs with multiple primary endpoints.
Related Concept Videos
Bioequivalence of Drugs: Drugs with Multiple Indications
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each indication due to...
Clinical Trials
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
Bioequivalence studies: Biowaivers
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
Bioavailability Study Design: Single Versus Multiple Dose Studies
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
Bioavailability Study Design: Healthy Subjects Versus Patients
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...